TMEM184B

Summary

TMEM184B (transmembrane protein 184B, HGNC:1310) is a protein-coding gene on chromosome 22q13.1, encoding Transmembrane protein 184B (Q9Y519). May activate the MAP kinase signaling pathway.

Predicted to enable transmembrane transporter activity. Predicted to be involved in transmembrane transport. Predicted to be active in membrane.

Source: NCBI Gene 25829 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 64 total
• MANE Select transcript: NM_012264

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1310
Approved symbol	TMEM184B
Name	transmembrane protein 184B
Location	22q13.1
Locus type	gene with protein product
Status	Approved
Aliases	HS5O6A, DKFZP586A1024, FM08, SLC51C2
Ensembl gene	ENSG00000198792
Ensembl biotype	protein_coding
Entrez	25829

Gene structure

Transcript identifiers

Ensembl transcripts: 30 — 20 protein_coding, 5 retained_intron, 3 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined

ENST00000361684, ENST00000361906, ENST00000403210, ENST00000411679, ENST00000436674, ENST00000457534, ENST00000464059, ENST00000466117, ENST00000474416, ENST00000488844, ENST00000504337, ENST00000633056, ENST00000633438, ENST00000883823, ENST00000883824, ENST00000883825, ENST00000883826, ENST00000883827, ENST00000883828, ENST00000883829, ENST00000883830, ENST00000883831, ENST00000883832, ENST00000883833, ENST00000883834, ENST00000883835, ENST00000913389, ENST00000956214, ENST00000956215, ENST00000956216

RefSeq mRNA: 3 — MANE Select: NM_012264 NM_001195071, NM_001195072, NM_012264

CCDS: CCDS13969

Canonical transcript exons

ENST00000361906 — 9 exons

Exon	Start	End
ENSE00001047965	38272884	38273010
ENSE00001375151	38219291	38221710
ENSE00003458707	38247770	38248019
ENSE00003494450	38226779	38226870
ENSE00003511045	38224785	38224979
ENSE00003526419	38231244	38231334
ENSE00003580377	38225424	38225593
ENSE00003599632	38230669	38230744
ENSE00003640288	38245935	38246100

Expression profiles

Bgee: expression breadth ubiquitous, 293 present calls, max score 96.14.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 45.9973 / max 265.4213, expressed in 1808 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
194137	37.8892	1800
194138	5.1995	1689
209473	1.0831	772
209472	0.9465	659
209471	0.8791	564

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
C1 segment of cervical spinal cord	UBERON:0006469	96.14	gold quality
right frontal lobe	UBERON:0002810	96.06	gold quality
spinal cord	UBERON:0002240	95.90	gold quality
stromal cell of endometrium	CL:0002255	95.84	gold quality
inferior vagus X ganglion	UBERON:0005363	95.45	gold quality
prefrontal cortex	UBERON:0000451	95.23	gold quality
cingulate cortex	UBERON:0003027	94.92	gold quality
anterior cingulate cortex	UBERON:0009835	94.90	gold quality
right hemisphere of cerebellum	UBERON:0014890	94.68	gold quality
right lung	UBERON:0002167	94.41	gold quality
apex of heart	UBERON:0002098	94.36	gold quality
thoracic aorta	UBERON:0001515	94.33	gold quality
ascending aorta	UBERON:0001496	94.32	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	94.13	gold quality
frontal cortex	UBERON:0001870	94.10	gold quality
inferior olivary complex	UBERON:0002127	93.91	gold quality
aorta	UBERON:0000947	93.87	gold quality
neocortex	UBERON:0001950	93.83	gold quality
medulla oblongata	UBERON:0001896	93.76	gold quality
sural nerve	UBERON:0015488	93.74	gold quality
amygdala	UBERON:0001876	93.63	gold quality
Brodmann (1909) area 9	UBERON:0013540	93.59	gold quality
popliteal artery	UBERON:0002250	93.57	gold quality
tibial artery	UBERON:0007610	93.56	gold quality
Brodmann (1909) area 10	UBERON:0013541	93.52	gold quality
cerebellar hemisphere	UBERON:0002245	93.49	gold quality
descending thoracic aorta	UBERON:0002345	93.48	gold quality
cerebellar cortex	UBERON:0002129	93.47	gold quality
subthalamic nucleus	UBERON:0001906	93.39	gold quality
upper lobe of left lung	UBERON:0008952	93.32	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-100618	yes	215.83
E-ANND-3	yes	8.56

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

132 targeting TMEM184B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-10401-5P	99.99	65.79	948
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-7152-3P	99.97	67.47	849
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580

Literature-anchored findings (GeneRIF, showing 2)

• C22orf5 (FM08) represents a novel gene found during a screening of gene that activate the MAPK pathway. (PMID:12761501)
• Data shows that miR-26a and miR-26b were significantly downregulated and their direct target, TMEM184B significantly up-regulated in oral squamous cell carcinoma cells. (PMID:25668004)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	tmem184ba	ENSDARG00000045147
danio_rerio	tmem184bb.2	ENSDARG00000090876
danio_rerio	tmem184bb.1	ENSDARG00000091956
mus_musculus	Tmem184b	ENSMUSG00000009035
rattus_norvegicus	Tmem184b	ENSRNOG00000022802
caenorhabditis_elegans		WBGENE00009574

Paralogs (3): SLC51A (ENSG00000163959), TMEM184C (ENSG00000164168), TMEM184A (ENSG00000164855)

Protein

Protein identifiers

Transmembrane protein 184B — Q9Y519 (reviewed: Q9Y519)

Alternative names: Putative MAPK-activating protein FM08

All UniProt accessions (4): A0A0J9YYJ3, Q9Y519, F2Z397, F8WCD4

UniProt curated annotations — full annotation on UniProt →

Function. May activate the MAP kinase signaling pathway.

Subcellular location. Membrane.

Similarity. Belongs to the TMEM184 family.

RefSeq proteins (3): NP_001182000, NP_001182001, NP_036396* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005178	Ostalpha/TMEM184C	Family

Pfam: PF03619

UniProt features (17 total): transmembrane region 7, modified residue 3, sequence conflict 3, region of interest 2, chain 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y519-F1	73.63	0.23

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 388, 402, 403

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 179 (showing top): MORF_MSH3, MORF_BRCA1, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, GTGCCTT_MIR506, MISSIAGLIA_REGULATED_BY_METHYLATION_UP, TCCAGAG_MIR518C, DOUGLAS_BMI1_TARGETS_UP, GTATGAT_MIR154_MIR487, CTTTGTA_MIR524, TGCCTTA_MIR124A, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, MORF_PPP2R5B, GOBP_TRANSMEMBRANE_TRANSPORT, GCM_PTK2

GO Biological Process (1): transmembrane transport (GO:0055085)

GO Molecular Function (1): transmembrane transporter activity (GO:0022857)

GO Cellular Component (1): membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transport	1
cellular process	1
transporter activity	1
transmembrane transport	1
cellular anatomical structure	1

Protein interactions and networks

STRING

506 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TMEM184B	DOK4	Q8TEW6	604
TMEM184B	ADAMTSL5	Q6ZMM2	572
TMEM184B	PRDM6	Q9NQX0	506
TMEM184B	PKP4	Q99569	470
TMEM184B	PRAP1	Q96NZ9	459
TMEM184B	SGSM3	Q96HU1	437
TMEM184B	MORN4	Q8NDC4	435
TMEM184B	MTMR11	A4FU01	419
TMEM184B	LSP1	P33241	419
TMEM184B	BAIAP2L2	Q6UXY1	418
TMEM184B	RPL37A	P12751	406
TMEM184B	LZTS3	O60299	395
TMEM184B	RPP40	O75818	388
TMEM184B	KLF3	P57682	386
TMEM184B	SPRY2	O43597	384

IntAct

24 interactions, top by confidence:

A	B	Type	Score
GPR21	TMEM120B	psi-mi:“MI:0914”(association)	0.530
TMEM184B	INPPL1	psi-mi:“MI:0914”(association)	0.530
SLC6A8	ILVBL	psi-mi:“MI:0914”(association)	0.530
BBS4	TRAFD1	psi-mi:“MI:0914”(association)	0.510
PDCD1	TMEM223	psi-mi:“MI:0914”(association)	0.350
ERGIC3	TMEM223	psi-mi:“MI:0914”(association)	0.350
CLEC2D	TMEM120B	psi-mi:“MI:0914”(association)	0.350
FPR2	GPR89A	psi-mi:“MI:0914”(association)	0.350
SLC22A9	GPR89A	psi-mi:“MI:0914”(association)	0.350
TIMM23	PIKFYVE	psi-mi:“MI:0914”(association)	0.350
ZFYVE27	PSMD11	psi-mi:“MI:0914”(association)	0.350
LPAR6	DEGS1	psi-mi:“MI:0914”(association)	0.350
ABCG8	TSPAN3	psi-mi:“MI:0914”(association)	0.350
HCST	TMEM120B	psi-mi:“MI:0914”(association)	0.350
CCR6	GPR89A	psi-mi:“MI:0914”(association)	0.350
MICB	TNFRSF10B	psi-mi:“MI:0914”(association)	0.350
GPR182	SLC12A8	psi-mi:“MI:0914”(association)	0.350
SYP	HAS3	psi-mi:“MI:0914”(association)	0.350
TMEM184B	SPAG9	psi-mi:“MI:0914”(association)	0.350
SLC15A3	GXYLT2	psi-mi:“MI:0914”(association)	0.350
SLC19A2	TMEM223	psi-mi:“MI:0914”(association)	0.350
TMEM184B	BBS4	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (55): TMEM184B (Affinity Capture-MS), TMEM184B (Affinity Capture-MS), SNIP1 (Affinity Capture-MS), REN (Affinity Capture-MS), CLASRP (Affinity Capture-MS), CCDC9 (Affinity Capture-MS), ACIN1 (Affinity Capture-MS), INPPL1 (Affinity Capture-MS), TMEM184B (Affinity Capture-MS), TMEM184B (Affinity Capture-MS), TMEM184B (Affinity Capture-MS), TMEM184B (Affinity Capture-MS), C17orf85 (Affinity Capture-MS), TMEM184B (Affinity Capture-MS), TMEM184B (Affinity Capture-MS)

ESM2 similar proteins: A2VDL9, A9UY97, F4JY11, G4YM00, G4Z2L3, O17204, O42579, P15920, P16393, P20715, P30628, P36142, P54960, P70549, P93766, Q09906, Q18071, Q1RMW2, Q29BL9, Q2U0S9, Q3UF25, Q3UFJ6, Q4QQS1, Q54PI4, Q54WM0, Q5BPZ5, Q5FWM8, Q5RBL0, Q5XIT3, Q5Z413, Q61086, Q651J5, Q657S5, Q6P6G5, Q6VVA6, Q6ZMB5, Q7TSW6, Q86TL2, Q8BG09, Q8MRQ4

Diamond homologs: A2VDL9, Q09906, Q17QL9, Q1RMW2, Q28CV2, Q3TPR7, Q3UFJ6, Q4QQS1, Q54PI4, Q54WM0, Q5BPZ5, Q5RET6, Q5ZMP3, Q6GQE1, Q6ZMB5, Q75JN3, Q810F5, Q8BG09, Q9NVA4, Q9Y519, F4JTN2, P36142, Q94CA0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

64 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	45
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2307 predictions. Top by Δscore:

Variant	Effect	Δscore
22:38221707:CGGC:C	acceptor_gain	1.0000
22:38221719:C:CT	acceptor_gain	1.0000
22:38224779:TCATA:T	donor_loss	1.0000
22:38224783:A:C	donor_loss	1.0000
22:38224784:C:CG	donor_loss	1.0000
22:38224975:CATGC:C	acceptor_gain	1.0000
22:38224976:ATGC:A	acceptor_gain	1.0000
22:38224976:ATGCC:A	acceptor_loss	1.0000
22:38224977:TGC:T	acceptor_gain	1.0000
22:38224977:TGCC:T	acceptor_loss	1.0000
22:38224978:GCCT:G	acceptor_loss	1.0000
22:38224980:C:CC	acceptor_gain	1.0000
22:38224980:C:CG	acceptor_loss	1.0000
22:38225418:GCTCA:G	donor_loss	1.0000
22:38225419:CTCAC:C	donor_loss	1.0000
22:38225420:TCA:T	donor_loss	1.0000
22:38225421:CAC:C	donor_loss	1.0000
22:38225454:TG:T	donor_gain	1.0000
22:38225592:CG:C	acceptor_gain	1.0000
22:38225594:C:CC	acceptor_gain	1.0000
22:38226777:A:AC	donor_gain	1.0000
22:38226778:C:CC	donor_gain	1.0000
22:38226867:TGGC:T	acceptor_gain	1.0000
22:38226869:GCC:G	acceptor_loss	1.0000
22:38226870:CCTGT:C	acceptor_loss	1.0000
22:38226871:C:CC	acceptor_gain	1.0000
22:38231242:A:AC	donor_gain	1.0000
22:38231243:C:CC	donor_gain	1.0000
22:38245929:CCTCA:C	donor_loss	1.0000
22:38245930:CTCAC:C	donor_loss	1.0000

AlphaMissense

2680 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
22:38221625:G:C	N356K	1.000
22:38221625:G:T	N356K	1.000
22:38230672:T:A	K174N	1.000
22:38230672:T:G	K174N	1.000
22:38221612:A:G	Y361H	0.999
22:38221630:G:C	H355D	0.999
22:38221635:G:T	A353D	0.999
22:38221636:C:G	A353P	0.999
22:38221639:C:G	D352H	0.999
22:38224825:G:C	F314L	0.999
22:38224825:G:T	F314L	0.999
22:38224827:A:G	F314L	0.999
22:38225542:G:C	S223R	0.999
22:38225542:G:T	S223R	0.999
22:38225544:T:G	S223R	0.999
22:38226863:A:G	L178P	0.999
22:38230682:C:A	R171M	0.999
22:38231307:A:G	L129P	0.999
22:38246059:C:A	Q78H	0.999
22:38246059:C:G	Q78H	0.999
22:38246087:A:G	L69P	0.999
22:38221602:T:C	Y364C	0.998
22:38221611:T:C	Y361C	0.998
22:38221612:A:C	Y361D	0.998
22:38221623:A:G	F357S	0.998
22:38221638:T:A	D352V	0.998
22:38221638:T:C	D352G	0.998
22:38221638:T:G	D352A	0.998
22:38221650:T:A	D348V	0.998
22:38226856:G:C	F180L	0.998

dbSNP variants (sampled 300 via entrez): RS1000024834 (22:38262727 G>A), RS1000031938 (22:38268858 C>T), RS1000055199 (22:38267534 G>A), RS1000066553 (22:38240524 A>G), RS1000083960 (22:38268585 G>A), RS1000092945 (22:38254847 C>G,T), RS1000098680 (22:38240910 T>C), RS1000217663 (22:38247535 G>A,T), RS1000245382 (22:38247326 C>T), RS1000264266 (22:38257269 T>C), RS1000269634 (22:38222032 A>G), RS1000307131 (22:38246446 G>A), RS1000308052 (22:38217651 A>C), RS1000347052 (22:38251700 G>A,C), RS1000381421 (22:38217288 T>G)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (1): neuromuscular disease (MONDO:0019056)

Orphanet (1): Neuromuscular disease (Orphanet:68381)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST002667_11	Mammographic density (dense area)	3.000000e-08
GCST002669_5	Percent mammographic density	5.000000e-09
GCST010002_82	Refractive error	2.000000e-13
GCST012226_156	Waist circumference adjusted for body mass index	1.000000e-11
GCST012231_21	A body shape index	3.000000e-09

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0005941	mammographic density measurement
EFO:0006503	dense area measurement
EFO:0006502	mammographic density percentage
EFO:0007789	BMI-adjusted waist circumference

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D009468	Neuromuscular Diseases	C10.668

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Acetaminophen	increases expression	2
Benzo(a)pyrene	affects methylation, increases methylation	2
Tetrachlorodibenzodioxin	increases expression, affects cotreatment	2
FR900359	increases phosphorylation	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	affects methylation	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Temozolomide	decreases expression	1
Air Pollutants	increases abundance, affects expression	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Doxorubicin	decreases expression	1
Fluorouracil	affects response to substance	1
Methapyrilene	increases methylation	1
Ozone	affects expression, increases abundance	1
Plant Extracts	affects cotreatment, decreases expression	1
Smoke	decreases expression	1
Dronabinol	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	decreases expression	1
Triiodothyronine	affects cotreatment, increases expression	1
Valproic Acid	increases expression	1
Aflatoxin B1	decreases methylation	1
Okadaic Acid	increases expression	1

Clinical trials (associated diseases)

198 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00331656	PHASE4	UNKNOWN	Comparative Study of Non-Invasive Mask Ventilation vs Cuirass Ventilation in Patients With Acute Respiratory Failure.
NCT00994552	PHASE4	UNKNOWN	Comparison of Pressure Support and Pressure Control Ventilation in Chronic Respiratory Failure
NCT00839033	PHASE3	TERMINATED	Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders
NCT00942227	PHASE3	COMPLETED	The Value of Traction in Treatment of Lumbar Radiculopathy
NCT00979108	PHASE3	COMPLETED	The Value of Traction in the Treatment of Cervical Radiculopathy
NCT01826487	PHASE3	COMPLETED	Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
NCT02090959	PHASE3	TERMINATED	An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy
NCT02436096	PHASE3	COMPLETED	A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
NCT02829814	PHASE3	TERMINATED	Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
NCT03179631	PHASE3	COMPLETED	Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy
NCT05126758	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
NCT05156320	PHASE3	COMPLETED	Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
NCT05337553	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
NCT05626855	PHASE3	ACTIVE_NOT_RECRUITING	Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
NCT06672237	PHASE3	RECRUITING	A Phase 3 Study of NTLA-2001 in ATTRv-PN
NCT01074359	PHASE2	TERMINATED	Safety and Efficacy Study of A0001 in Patients With the A3243G Mitochondrial DNA Point Mutation
NCT01371149	PHASE2	COMPLETED	Patient -Ventilator Interaction in Chronic Respiratory Failure
NCT02022072	PHASE2	TERMINATED	Evaluation of Vital Capacity
NCT03127514	PHASE2	COMPLETED	AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT03406780	PHASE2	COMPLETED	A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
NCT03921528	PHASE2	COMPLETED	An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
NCT05479981	PHASE2	COMPLETED	Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients
NCT06339580	PHASE2	RECRUITING	Assessment of Volume-targeted Ventilation in Patients With Neuromuscular Disease
NCT07071935	PHASE2	NOT_YET_RECRUITING	A Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS)
NCT07287189	PHASE2	RECRUITING	Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT00252252	PHASE1	COMPLETED	AutoVPAP Versus VPAP; Assessment of Sleep and Ventilation
NCT01560741	PHASE1	UNKNOWN	Telemedicine and Ventilator Titration in Chronic Respiratory Patients Initiating Non-invasive Ventilation
NCT01621984	PHASE1	COMPLETED	Therapeutic Riding and Neuromuscular Disease
NCT01758510	PHASE1	COMPLETED	Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis
NCT03440034	PHASE1	COMPLETED	Study of Pioglitazone in Sporadic Inclusion Body Myositis
NCT05730842	PHASE1	COMPLETED	Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers
NCT03272802	PHASE2/PHASE3	UNKNOWN	Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT00860951	PHASE1/PHASE2	COMPLETED	P300 Brain Computer Interface Keyboard to Operate Assistive Technology
NCT02362425	PHASE1/PHASE2	COMPLETED	Antioxidant Therapy in RYR1-Related Congenital Myopathy
NCT00001201	Not specified	COMPLETED	Evaluation of Neuromuscular Disease
NCT00002044	Not specified	COMPLETED	A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases
NCT00004553	Not specified	COMPLETED	Electromyography to Diagnose Neuromuscular Disorders
NCT00015470	Not specified	COMPLETED	Diagnostic Evaluation of Patients With Neuromuscular Disease
NCT00017745	Not specified	COMPLETED	Phenotype/Genotype Correlations in Neuromuscular Disorders
NCT00695591	Not specified	COMPLETED	Home Sleep Testing in Neuromuscular Disease Patients